Pharos iBio Co., Ltd. (388870) Stock Forecast & Analysis
Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Pharos iBio Co., Ltd. (388870:KRX), powered by AI.
- Current Price
- ₩7,000
- P/E Ratio
- -8.4
- Market Cap
- 90.6B
- Sector
- Common Stock
What is the Pharos iBio Co., Ltd. stock price forecast?
Pharos iBio Co., Ltd. is currently trading at ₩7,000. View real-time AI analysis on Alpha Lenz.
What is Pharos iBio Co., Ltd. insider trading activity?
View the latest insider trading data for Pharos iBio Co., Ltd. on Alpha Lenz.
What is Pharos iBio Co., Ltd.'s P/E ratio?
Pharos iBio Co., Ltd.'s P/E ratio is -8.4.
Pharos iBio Co., Ltd.
KRX · 388870“Pharos iBio Co., Ltd. trades at a P/E of -8.4 (undervalued) with modest ROE of -66.1%.”
Ask for details →Company Overview
Pharos iBio Co., Ltd. is a prominent entity within the biopharmaceutical sector, focusing on the research, development, and commercialization of innovative therapies. This company plays a fundamental role in advancing treatments for various medical conditions, making it an integral participant in the healthcare and life sciences industries. Pharos iBio Co., Ltd. leverages cutting-edge biotechnology to create solutions that address unmet medical needs, aiming to improve patient outcomes and enhance the quality of life. In the financial markets, Pharos iBio Co., Ltd. engages with investors and stakeholders interested in the growth and potential of biopharmaceutical innovations and breakthroughs, contributing to the dynamic landscape of global healthcare.
Company Statistics
FY 2025Profile
Margins
Valuation
Growth (CAGR)
Returns
Financial Health
“Pharos iBio Co., Ltd. trades at a P/E of -8.4 (undervalued) with modest ROE of -66.1%.”
Ask for details →Frequently Asked Questions
Pharos iBio Co., Ltd. (ticker: 388870) is a company listed on KRX in the Common Stock sector (Common Stock). Market cap is $90.6B.
The current price is ₩7,000 with a P/E ratio of -8.42x and P/B of 6.51x.
ROE is -66.11%.